La Mantia L, Eoli M, Salmaggi A, Milanese C
Istituto Neurologico C. Besta, Milano, Italy.
Ital J Neurol Sci. 1996 Apr;17(2):135-9. doi: 10.1007/BF02000844.
To verify whether the outcome in placebo-treated MS patients actually corresponds to that expected on the basis of the natural history and pretrial evolution of the disease, we here review the results of clinical trials conducted according to a placebo-controlled, randomized design, regardless of the experimental therapy used. The frequency of relapse in remitting-relapsing patients decreases during follow-up, and disability in progressive cases increases more slowly than before enrollment. These data should be borne in mind when evaluating the impact of experimental drugs on the natural course of the disease.
为了验证安慰剂治疗的多发性硬化症（MS）患者的实际结局是否真的与基于该疾病自然史和治疗前病程所预期的结局相符，我们在此回顾根据安慰剂对照、随机设计开展的临床试验结果，而不考虑所使用的实验性疗法。复发缓解型患者的复发频率在随访期间降低，进展型患者的残疾进展速度比入组前更慢。在评估实验性药物对疾病自然病程的影响时，应牢记这些数据。
